bexobrutideg
NX-5948 · bexdeg Small Molecule Target: BTK
Nurix Therapeutics
Most recent annual filing: 2026-01-28
Pipeline (15 active programs)
zelebrudomide
NX-2127 Small Molecule Target: BTK, IKZF1, IKZF3
NX-1607
Small Molecule Target: CBL-B
- Undisclosed indication
NX-0479
GS-6791 Small Molecule Target: IRAK4
- Undisclosed indication
NX-3911
Small Molecule Target: STAT6
- Undisclosed indication
bexobrutideg
NX-5948 Small Molecule Target: BTK
Technology platforms
DEL-AI
Fully AI-integrated, DNA-encoded library (DEL)-powered drug discovery engine for targeted protein degradation (TPDs and DACs); disease-agnostic; applied to oncology, inflammation, autoimmunity and other therapeutic areas; leverages 5 billion DEL compounds and machine learning for ligand discovery, degrader design, and optimization.
DAC · Pfizer
Degrader Antibody Conjugate platform combining targeted protein degrader payloads with cell/tissue-selective antibody delivery; designed for oncology and non-oncology; partnered with Pfizer for ADC/DAC development.
Biotech Distilled coverage (4)
- 2026-07-09 UPDATE: Nurix Therapeutics (NRIX) - The Re-Rate Delivered
- 2026-06-11 UPDATE: Nurix Therapeutics (NRIX) - The Earlier-Line Read-Through
- 2026-06-08 UPDATE: Nurix Therapeutics (NRIX) - Roche Validates the Molecular Assassin
- 2026-04-13 Nurix Therapeutics (NRIX) - Scientific Deep Dive for Bexobrutideg and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.